CFCM INTELLIGENCE
Technology, reagents, companies and regulation — tracked through dated events, primary sources and explicit evidence boundaries.
Platforms, software and changing capabilities.
Clones, formats, intended use and availability.
Portfolios, partnerships and market presence.
Primary documents, jurisdictions and effective dates.
Only records released through the current editorial workflow appear here. Dates describe the underlying event and source, not the date CFCM discovered it. Independent scientific review is not implied unless explicitly stated.
No market records have completed editorial review yet.
Regulatory
Revision 5 updates the Rule 7 rationale and examples.
Event date
September 9, 2026
Source publication date
September 9, 2026
EU
Published non-binding guidance; no new statutory effective date inferred
Read the evidence →mdcg-2020-16-rev5-rule7-2026-09-09
TECHNOLOGY RADAR
Announcements, independent evidence and clinical validation are assessed separately.
Read the CFCM analysis →REAGENT WATCH
Identity, clone, catalogue number and jurisdiction matter when interpreting a product update.
Explore antibody selection →COMPANY WATCH
A distributor listing, a conference presentation and clinical authorisation describe different developments.
Read the market analysis →REGULATORY WATCH
Track the authority, document, jurisdiction and effective date before drawing operational conclusions.
Read the regulatory analysis →Primary evidence → What it demonstrates → Evidence boundary → Practical implications → CFCM view.
Manufacturer statements are identified as such. Unknown dates and unconfirmed availability remain unknown. Editorial priority is separate from publication approval.
Editor, affiliation and independence →